These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 21747976)

  • 21. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
    Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
    Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mineralocorticoid receptor activation in obesity hypertension.
    Nagase M; Fujita T
    Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
    Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall.
    Jia G; Aroor AR; Sowers JR
    Cardiovasc Res; 2017 Jul; 113(9):1055-1063. PubMed ID: 28838041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
    Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
    Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction.
    Jing F; Mogi M; Horiuchi M
    Mol Cell Endocrinol; 2013 Sep; 378(1-2):23-8. PubMed ID: 22465098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deficiency of T-type Ca
    Thuesen AD; Finsen SH; Rasmussen LL; Andersen DC; Jensen BL; Hansen PBL
    Am J Physiol Renal Physiol; 2019 Aug; 317(2):F254-F263. PubMed ID: 31042060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
    Takeda Y; Yoneda T; Demura M; Usukura M; Mabuchi H
    Circulation; 2002 Feb; 105(6):677-9. PubMed ID: 11839620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Aldosterone as an endogenous cardiovascular toxin and the options for its therapeutic management].
    Horký K
    Vnitr Lek; 2011 Dec; 57(12):1012-6. PubMed ID: 22277034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis.
    Sato A; Funder JW; Saruta T
    Am J Hypertens; 1999 Sep; 12(9 Pt 1):867-73. PubMed ID: 10509543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TRAF3IP2 mediates aldosterone/salt-induced cardiac hypertrophy and fibrosis.
    Sakamuri SS; Valente AJ; Siddesha JM; Delafontaine P; Siebenlist U; Gardner JD; Bysani C
    Mol Cell Endocrinol; 2016 Jul; 429():84-92. PubMed ID: 27040306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant Rac1-mineralocorticoid receptor pathways in salt-sensitive hypertension.
    Kawarazaki W; Fujita T
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):929-36. PubMed ID: 24111570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mineralocorticoid antagonism and cardiac hypertrophy.
    Nagata K
    Curr Hypertens Rep; 2008 Jun; 10(3):216-21. PubMed ID: 18765093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes.
    Tsai CF; Yang SF; Chu HJ; Ueng KC
    Int J Cardiol; 2013 Oct; 169(1):17-28. PubMed ID: 24120080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hypertension-induced fibrosis: a balance story].
    Azibani F; Fazal L; Chatziantoniou C; Samuel JL; Delcayre C
    Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):150-5. PubMed ID: 22681982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular actions of aldosterone.
    Briet M; Schiffrin EL
    J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure.
    Weber KT; Brilla CG; Campbell SE; Zhou G; Matsubara L; Guarda E
    Blood Press; 1992 Aug; 1(2):75-85. PubMed ID: 1366263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
    Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
    Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.
    Packer M
    Circulation; 2018 Apr; 137(15):1614-1631. PubMed ID: 29632154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.